0000000000323955

AUTHOR

Bernd Weber

showing 5 related works from this author

DHCR_OST-Cannabis_Alcohol_supplementary_2018-10-30_xyz151015746ed84_3-converted – Supplemental material for Alcohol and Cannabis Consumption Does Not…

2019

Supplemental material, DHCR_OST-Cannabis_Alcohol_supplementary_2018-10-30_xyz151015746ed84_3-converted for Alcohol and Cannabis Consumption Does Not Diminish Cure Rates in a Real-World Cohort of Chronic Hepatitis C Virus Infected Patients on Opioid Substitution Therapy—Data From the German Hepatitis C-Registry (DHC-R) by Stefan Christensen, Peter Buggisch, Stefan Mauss, Klaus HW Böker, Tobias Müller, Hartwig Klinker, Tim Zimmermann, Yvonne Serfert, Bernd Weber, Jens Reimer and Heiner Wedemeyer in Substance Abuse: Research and Treatment

111799 Public Health and Health Services not elsewhere classifiedFOS: Health sciences
researchProduct

Alcohol and Cannabis Consumption Does Not Diminish Cure Rates in a Real-World Cohort of Chronic Hepatitis C Virus Infected Patients on Opioid Substit…

2019

Background: The importance of alcohol and cannabis consumption for the effectiveness of treatment of chronic hepatitis C virus (HCV) infection with direct acting antivirals (DAAs) in people on opioid substitution therapy (OST) has not been investigated in detail. Methods: We investigated sustained virological response (SVR) rates and proportion of lost to follow-up (LTFU) between OST (n = 739) and non-OST patients (n = 7008) in the German Hepatitis C-Registry (Deutsches Hepatitis C-Register, DHC-R), which is a national multicenter prospective non-interventional real-world registry. Non-OST patients comprised patients with former/current drug use (non-OST/DU; n = 1500) and patients never con…

cannabismedicine.medical_specialtyMedizinShort ReportAlcoholVirus03 medical and health scienceschemistry.chemical_compound0302 clinical medicineChronic hepatitisInternal medicinereal-world settingmedicine030212 general & internal medicinePWIDConsumption (economics)biologyOSTbusiness.industryalcohollcsh:Public aspects of medicinefungilcsh:RA1-1270Hepatitis Cbiology.organism_classificationmedicine.diseaseSVR12Psychiatry and Mental healthchemistryCohortHCV030211 gastroenterology & hepatologyCannabisbusinessOpioid substitution therapySubstance abuse : research and treatment
researchProduct

Predictive factors for sustained virological response after treatment with pegylated interferon α-2a and ribavirin in patients infected with HCV geno…

2014

BackgroundPrevious trials have often defined genotype 2 and 3 patients as an "easy to treat" group and guidelines recommend similar management.AimsThe present study looks for differences between the two genotypes and analyzes predictive factors for SVR.MethodsProspective, community-based cohort study involving 421 physicians throughout Germany. The analysis includes 2,347 patients with untreated chronic HCV genotype 2 (n = 391) and 3 (n = 1,956) infection treated with PEG-IFN α-2a plus ribavirin between August 2007 and July 2012.ResultsWhen compared with genotype 2 patients, those with genotype 3 were younger, had a shorter duration of infection, lower values of total cholesterol, LDL chole…

DrugAdultMalemedicine.medical_specialtyMultivariate analysisGenotypeGastroenterology and hepatologyHepacivirusmedia_common.quotation_subjectScienceHepacivirusGastroenterologyCohort Studieschemistry.chemical_compoundInternal medicineGermanyAlcohols Cholesterol; Dose prediction methods; Drug therapy; Fibrosis; Multivariate analysis; Physicians; Treatment guidelinesGenotypemedicineHumansLiver diseasesmedia_commonMedicine and health sciencesMultidisciplinarybiologybusiness.industryRibavirinQRHepatitis CMiddle Agedbiology.organism_classificationmedicine.diseaseHepatitis C3. Good healthClinical trialInfectious hepatitischemistryImmunologyMedicineFemalebusinessCohort studyResearch ArticlePloS one
researchProduct

Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?

2018

BACKGROUND AND AIMS There is limited real-world information on the effectiveness of antiviral treatment of chronic hepatitis C virus (HCV) infection with direct-acting antivirals (DAA) in people on opioid substitution therapy (OST). This study compared sustained virological response (SVR) rates and proportion of lost to follow-up (LTFU) between OST and non-OST patients in the German Hepatitis C-Registry (DHC-R). DESIGN National multi-centre prospective real-world registry (German Hepatitis C-Registry, DHC-R). Non-OST patients comprised patients with former/current drug use (non-OST/DU) and patients never consuming drugs (non-OST/NDU). SETTING A total of 254 medical centres in Germany, inclu…

HepatitisDrugeducation.field_of_studymedicine.medical_specialtyCirrhosisbusiness.industrymedia_common.quotation_subjectfungiPopulationMedicine (miscellaneous)medicine.diseaseClinical Practice03 medical and health sciencesPsychiatry and Mental health0302 clinical medicineInternal medicineMedicine030211 gastroenterology & hepatology030212 general & internal medicineAntiviral treatmentbusinesseducationOpioid substitution therapyDirect actingmedia_commonAddiction
researchProduct

Safety and tolerability of slow-release oral morphine versus methadone in the treatment of opioid dependence

2014

Opioid substitution treatment (OST) for opioid dependence may be limited by adverse events (AEs). Increasing the range of therapeutic options optimizes outcomes and facilitates patient management. An international, multi-center, two-phase study investigated the efficacy and safety of slow-release oral morphine (SROM) versus methadone in patients receiving methadone therapy for opioid dependence. In phase 1 (two way cross-over, 11 weeks each period) patients were randomized to SROM or methadone oral solution. In phase 2 (25 weeks), patients continued treatment with SROM (group A) or switched from methadone to SROM (group B). In total, 211 out of 276 completed phase 1 and 198 entered phase 2 …

AdultMaleInternational CooperationAdministration OralMedicine (miscellaneous)QT intervalHeroinOpiate Substitution TreatmentHumansMedicineIn patientOral morphineAdverse effectCross-Over StudiesMorphinebusiness.industryOpioid-Related DisordersEuropePsychiatry and Mental healthClinical PsychologyTreatment OutcomeOpioidTolerabilityDelayed-Action PreparationsAnesthesiaFemalePshychiatric Mental HealthbusinessMethadonemedicine.drugMethadoneJournal of Substance Abuse Treatment
researchProduct